THE AMINO-TERMINUS OF JAK3 IS NECESSARY AND SUFFICIENT FOR BINDING TOTHE COMMON GAMMA-CHAIN AND CONFERS THE ABILITY TO TRANSMIT INTERLEUKIN 2-MEDIATED SIGNALS
M. Chen et al., THE AMINO-TERMINUS OF JAK3 IS NECESSARY AND SUFFICIENT FOR BINDING TOTHE COMMON GAMMA-CHAIN AND CONFERS THE ABILITY TO TRANSMIT INTERLEUKIN 2-MEDIATED SIGNALS, Proceedings of the National Academy of Sciences of the United Statesof America, 94(13), 1997, pp. 6910-6915
JAK3 is a protein tyrosine kinase that specifically associates with th
e common gamma chain (gamma(c)), a shared subunit of receptors for int
erleukin (IL) 2, 4, 7, 9, and 15. Patients deficient in either JAK3 or
gamma(c) presented with virtually identical forms of severe combined
immunodeficiency (SCID), underscoring the importance of the JAK3-gamma
(c) interaction. Despite the key roles of JAK3 and gamma(c) in lymphoc
ytic development and function, the molecular basis of this Interaction
remains poorly understood, In this study, we have characterized the r
egions of chimeric involved in gamma(c) association. By developing a n
umber of chimeric JAK3-JAK2 constructs, we show that the binding speci
ficity to gamma(c) can be conferred to JAK2 by transferring the N-term
inal domains of JAK3. Moreover, those JAK3-JAK2 chimeras capable of bi
nding gamma(c) were also capable of reconstituting IL-2 signaling as m
easured by inducible phosphorylation of the chimeric JAK3-JAK2 protein
, JAK1, the IL-2 receptor beta chain, and signal transducer and activa
tor of transcription 5A. Subsequent deletion analyses of JAK3 have ide
ntified the N-terminal JH7-6 domains as a minimal region sufficient fo
r gamma(c) association, Furthermore, expression of the mutant containi
ng only tile JH7-6 domains effectively competed with full-length JAK3
for binding to gamma(c). We conclude that the JH7-6 domains of JAK3 ar
e necessary and sufficient for gamma(c) association. These studies off
er clues toward a broader understanding of JAK-mediated cytokine signa
ling and may provide a target for the development of novel therapeutic
modalities in immunologically mediated diseases.